A minimally invasive heart procedure may be a better first-line treatment than medication for people living with advanced ...

In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.

Over the last weekend, Chicago played host to the 2026 edition of the Heart Rhythm Society's annual conference (HRS 2026).

Guidelines recommend a trial of antiarrhythmic drugs before catheter ablation for persistent atrial fibrillation. Whether pulsed field ablation (PFA) may be a preferred initial treatment is ...

Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 ...

New research presented at the Heart Rhythm Society’s 2026 meeting shows that 14-day continuous monitoring with iRhythm’s Zio patch detects significantly more atrial fibrillation recurrences than the ...

Two retrospective studies detected arrhythmias beyond 48 hours in 30% of patients post cardiac ablation and in 60% of ...

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation ...

Adagio Medical (Nasdaq:ADGM) today announced new six-month results from its FULCRUM-VT clinical trial evaluating its ablation ...

Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where ...

There are both clinical and economic implications, as payers have been discouraging ablation in this population, one expert ...

A major international trial led by the University of British Columbia found that starting treatment with catheter-based pulsed field ablation offers better rhythm control than medication for patients ...